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A B S T R A C T
Background: Survival of children with cancer in resource-limited regions is very poor compared to better-re-
sourced regions. Retinoblastoma (RB) is a childhood cancer that is commonly reported in many regions of Africa.
RB may be safely and effectively treated by non-specialists, which could facilitate more widespread availability
of treatment in under-resourced areas.
Methods: A ten-year consecutive series of children with RB treated at Ruharo Eye Centre between December
2009 and November 2019 was prospectively followed up. Chemoreduction followed by surgery is the standard
approach to therapy. Costs of therapy and also of travel and food are borne by the program which is unaffordable
to most families and necessitates donors. Survival by stage of RB and number of eyes affected was described
using Kaplan-Meier plots. Visual acuity was assessed for all children with bilateral disease and the retention of
sight during follow-up assessed.
Results: Among 665 children with RB, 18.2 % (121 children) presented with metastatic (Stage 4) RB with only
two of these children surviving >24 months. Five-year survival was 60.2 % among all children with RB rising to
93.3 % and 87.2 % for children with unilateral and bilateral Stage 1 disease, respectively. Among 184 children
with bilateral disease, 130 (70.7 %) retained some level of sight following primary treatment with 91 of those
(49.5 % of all bilateral children) retaining vision up to their death or to the end of follow-up.
Conclusion: Many children in Uganda present with advanced RB and curative treatment is not possible in this
setting. Children diagnosed and treated early have good prospects of survival. Retention of sight among many
bilaterally affected children is achievable, facilitating access to normal education. Therefore, the strategic
priorities for improving survival are changing community perceptions so that children with eye problems are
brought without delay, and widening access to modern treatment by using genereal health workers with stan-
dard drugs, backed by financial, social and peer support.
1. Introduction
A recent review of global childhood cancer burden finds that data
from low- and middle-income countries are scarce although 90 % of
children with cancer reside there. It goes on to suggest that survival is
substantially worse than in high income countries [1]. Retinoblastoma
(RB) is one of the most commonly reported childhood cancers in Africa,
and was said to be the commonest eye cancer overall until overtaken in
sub-Saharan Africa by HIV-associated conjunctival carcinoma [2]. In
East Africa, access to treatment for RB is sparse with only a few uni-
versity departments offering modern treatment while some neigh-
bouring countries have no provision. Our nation-wide study in Uganda
between 2006 and 2009 documented 3-year survival of only 45 %
among children treated at Ruharo Eye Centre when only enucleation
with occasional radiotherapy (cobalt 60) were available [3]. This
contrasts with near 100 % survival in countries with adequate resources
[4–6]. Our further study (2006–2013) showed a 37 % reduction in the
risk of dying from RB in Uganda following the introduction of
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chemoreduction using standard chemotherapy at Ruharo Eye Centre
late in 2009 [7]. We also showed that non-specialists could safely ad-
minister the treatment potentially making it much more widely avail-
able. A cost-benefit analysis was favourable in terms of life years saved
and blind years prevented. However, the expense of this treatment is
beyond most families and full financial support including transport and
food was essential for preventing abandonment of treatment.
This treatment approach has continued as routine since 2013, and
the current report documents outcome for all children intended to be
treated with chemotherapy since 2009. A large number of children are
included with a high rate of treatment completion and follow up. For
children with heritable bilateral disease who risk loss of both eyes, le-
vels of sight conserved or lost over the course of the treatment is traced.
Despite improved survival, the major cause of death remains late pre-
sentation highlighting the importance of palliative management of in-
curable RB. The numbers of new patients have increased markedly and
the program now includes second line agents if standard treatment fails,
intravitreal chemotherapy, intensified use of local modalities (laser and
cryotherapy) and improved prosthetics after enucleation. Clinical de-
tails of these are presented here only in brief (see Supplement for fur-
ther details), and emphasis will be on reproducible strategies for success
in under-resourced regions.
The context of this report is recognition that for much of sub-
Saharan Africa more advanced investigations and treatments like rou-
tine cranial scans, intra-arterial chemotherapy, conformal radiotherapy,
granulocyte-colony stimulating factor and retinal photography are not
yet available or are unaffordable. However, despite this, major im-
provement in outcome is achievable now and is long overdue.
Moreover, since late presentation accounts for most mortality, the lar-
gest improvement by far would result not from the introduction of
expensive advanced technology but from changes in community per-
ceptions. Communities need to understand that curative treatment is
available and, at Ruharo Eye Centre, financially supported. Health care
workers need to consider RB and facilitate early referral to appropriate
centres. With successful outcomes, the stigma and fear of facial defor-
mity after enucleation will be avoided by good prosthetics. Thus, the
priorities are community education and the wide availability of effec-
tive referral centres with financial and family support.
2. Materials and methods
This is a prospective, observational study of a consecutive series of
children presenting at Ruharo Eye Centre, Uganda, between December
2009 and November 2019 with a final diagnosis of RB. All children
were intended to be treated with standard chemotherapy as the initial
intervention (chemoreduction). Enrolment, information and consent,
record keeping and chemotherapy (vincristine, etoposide and carbo-
platin using peripheral veins) are as in previous papers [3,7]. Fuller
details of clinical management are available in the Supplement.
Staging of RB on enrolment to this study was based upon the
International Retinoblastoma Staging System (IRSS) [8]. This system
divides the entire intra- and extra-ocular spectrum into four stages.
Stage 1 is complete resection of intraocular tumour or its ablation by
chemotherapy, expecting 100 % survival. Stage 2 is microscopic re-
sidual tumour (also termed minimal metastatic dissemination) with
good but not total survival. Stage 3 is macroscopic extension to orbit or
local lymph nodes, further lowering survival. Stage 4 is metastatic
disease (usually intracranial or bone marrow) with minimal survival
expected. However, the system as published presumes full resources
and is brief, so more detailed criteria suitable for resource-limited re-
gions were selected from published systems using both clinical and
pathological features and used for this study (Box 1) [9–12].
In earlier years, full histology was sometimes unavailable but is now
obtained from Mbarara University Pathology Department, with addi-
tional review carried out in Leeds, UK. After fixation of the enucleated
eye for 48 h the resection margin of the optic nerve is marked with
Indian Ink and the proximal portion removed for separate processing.
The initial gross cut of the eye into two halves is then done by the
surgeon to provide immediate clinical information and for photo-
graphic records before being sent for detailed histology. Recording of
results includes the clinical and pathological TNM (Tumour, Node,
Metastasis) system to aid staging (Box 1 [9]).
Follow up is on-going and was intensified starting in the last six
months of the study, aiming to update outcomes for every child as re-
cently as possible. Follow-up is counted as complete if, in this period or
onwards, the child has been seen in clinic or at home visit, or family
contacted by telephone. For those whose follow up was already four
years or more it was counted complete if contacted in the final year of
the study. For non-survivors, follow-up was to death, with a few in-
accessible terminal children presumed died and date estimated.
Survival is reported with Kaplan-Meier estimates stratified by stage
and by involvement of one or both eyes. Vision in children with bi-
lateral disease but having at least one conserved eye was assessed by
formal testing of visual acuity appropriate for age, or estimated from
fundal appearance. To predict educational needs, final central vision
was divided into 4 broad categories: normal central vision (6/18 or
better, macula uninvolved), moderate impairment (tumour or scar en-
croaching on macula, fovea spared), major impairment (macula ab-
lated) and blind (usually enucleation). Data were collected and held
using Epi Info (Version 7.2; Centers for Disease Control, USA) [13] and
all analyses were undertaken using SAS software (Version 9.4, The SAS
Institute, Cary, NC, USA) [14].
3. Results
In 10 years, 665 children with RB were enrolled; annual enrolments
increased over this period with children travelling from across Uganda
and from neighbouring countries to access RB treatment at Ruharo
(Fig. 1). Overall, 26% of children had bilateral disease, there was a
small male majority and the median age at diagnosis was 29 months
(Table 1, Fig. 2). Nearly all children completed follow-up (range 1 day
to 128.4 months) and there was a low level on non-compliance
(Table 1). There were 23 children (18 bilateral, 5 still unilateral) from
12 families having siblings or parents with RB, all others reporting no
family history. Five children tested positive for Human Im-
munodeficiency Virus on admission, of whom three were on anti-
retroviral therapy and two reverted to negative having maternal anti-
bodies. One of these three had metastatic disease and died. The others
tolerated chemotherapy uneventfully and are well. Seven children died
within 4 weeks after chemotherapy when leucopaenia could have been
responsible. They were at home so details of the cause of death are
uncertain but two were advanced cases for palliation only. For context,
in the 5 years 2014–2018 there were 1968 chemotherapy courses given.
To illustrate the annual workload of the program, in the calendar
year 2018 there were 768 admissions for the 105 newly presenting
children and those of previous years still under treatment or mon-
itoring. There were 460 courses of chemotherapy, 99 enucleations, 106
local treatments (laser and cryotherapy) and 31 intravitreal injections.
For these procedures, and for monitoring progress, 390 general anaes-
thetics were given. There were no significant complications; 4 children
had mild reactions to carboplatin which was permanently discontinued.
In addition, 7 children with other ocular or orbital malignancies who
had been referred on suspicion of RB were treated in collaboration with
the Children’s Cancer Unit at Mbarara Regional Referral Hospital.
After stratifying the children by the modified IRSS criteria (Box 1),
Fig. 3 shows their distribution and Fig. 4 presents their survival as
Kaplan-Meier curves, separately for unilateral and bilateral disease.
Children who received no treatment because parents or carers declined,
or if treatment considered vital for survival was interrupted for more
than 6 months, are presented separately so as not to obscure what is
currently achievable. Overall five-year survival was 60.2 %. Stage of
disease was a strong determinant of survival: Five-year survival in Stage
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1 was 87.8 %, decreasing to 73.0 % in Stage 2, 21.6 % of children in
Stage 3 survived 5 years and only two children with Stage 4 disease
have survived 2 years. Survival among the 34 children whose treatment
was declined or interrupted was comparable overall to those with Stage
3 disease. Although curves for unilateral and bilateral differ, the p-va-
lues comparing them were non-significant at any stage.
For the 184 children with bilateral disease who are therefore at risk
of blindness (omitting 5 currently with unilateral disease but with
siblings or parents with RB so are presumed to have heritable disease),
71 (38.6 %) were assessed as having full vision at the time of enrolment
whilst 48 (26.1 %) were assessed as blind. At the end of their primary
treatment 8 children had lower vision than prior to treatment however
23 children showed immediate improvement in visual acuity (Table 2).
Among the 130 bilateral children with some vision after primary
treatment, 91 (70.0 %) retained some vision to their death or to the end
of follow-up (Fig. 5); 35 (26.9 %) had enucleation after the end of
primary treatment. Children with severe visual impairment at the end
of primary treatment were the least likely to retain vision throughout
follow-up: no child has retained vision beyond 30 months as yet
(Fig. 5). Overall, 60.5 % of currently surviving children with bilateral
disease retain some vision, with 49.6 % retaining full central vision.
Currently the affected eyes of 10 unilateral children are conserved as
are both of 6 children with bilateral disease, the remainder have had
enucleation or are expected to need it.
4. Discussion
Eye workers in Africa are sadly familiar with receiving distressed
children having advanced, fungating, incurable tumours. The wide gap
in survival between world regions is well documented to be dependent
on resources. With the large childhood populations in regions such as
Africa, most of the world tally of deaths occur there [2,15]. In this
‘majority world’ it is time to stop accepting this as unchangeable.
Modern treatment needs urgently to become much more widely avail-
able now and not wait for the arrival of a fully resourced university
nearby. Although RB management should be restricted to referral
centres with the necessary expertise, equipment and funding, the issue
is whether non-specialists in general eye units can develop the neces-
sary skills so as to expand availability. Cancer is usually managed by a
multidisciplinary team led by oncologists, with the surgeon responsible
only for the biopsy or excision, but at present oncologists are few in
Africa. Retinoblastoma is exceptional in requiring the surgeon (the
ophthalmologist) to be responsible not only for the one-off enucleation
but also for frequent intraocular examinations and treatments. Because
of this and the relatively low toxicity of the chemotherapy, ophthal-
mologists are in a position to lead the team and make the management
decisions. This study confirms that safe, effective treatment is possible
in this way which may help to rectify the lack of treatment accessibility
identified in the global studies [1,15]. This study also shows that the
frequent abandonment of treatment often reported is not inevitable,
and that near total follow up is achievable in the age of mobile tele-
phones [16].
If we consider a schematic pathway to treatment (Fig. 6), pre-
sentation at a known RB centre (Ruharo for example) is the starting
point for children to access the types of effective treatment detailed
here. It is not known how many children develop RB in Uganda nor is it
known what proportion of affected children are presented for diagnosis
and eventual treatment. Regrettably, this study again highlights the
problem of delayed presentation, allowing only palliation for many
children (Stage 4 in Fig. 4). Delay is understandable for parents with
large families living by subsistence far away from treatment centres
who do not perceive urgency for something painless in one child’s eye.
However, even more affluent parents not from afar may also delay, not
perceiving the value of accessing services. Some have ideological rea-
sons for delaying, or for declining, free treatment even when they do
come. Programs to influence public understanding are now running,
and change in socio-cultural attitudes must be the prime target for re-
ducing the rate of death due to RB. This can only come about when the
community has learnt that effective, financially supported treatment is
now available, and when healthcare workers facilitate rapid referral.
The rising numbers of children presenting at Ruharo show that com-
munity awareness has grown and possibly that a greater proportion of
affected children are receiving treatment. Currently this is also resulting
in a rise in the number of children for whom only palliation is possible,
Box 1
Modified International Retinoblastoma Staging System (IRSS) used in this study, adapted from Chantada et al. 2006, Amin et al. 2017, Shields et al.
2006 and Linn Murphree et al, 2005.
Stage 1 Totally intraocular, with/without local invasion
Clinical cT1 ICRB group A/B intraretinal tumours sub-retinal fluid =< 5mm from base
cT2 ICRB group C/D, subretinal/vitreous seeds, subretinal fluid =>5mm from base
Pathology pT1 No choroid or pre- / intralaminar invasion, no anterior segment invasion
pT2 a. Focal choroid, pre / intralaminar invasion
b. Invasion of stroma of iris, trabeculum or Schlemm’s canal
Stage 2 Microscopic residual tumour
Clinical cT3 a. Pre- / phthisis
b. Ciliary body, lens, anterior chamber invasion
c. Raised intraocular pressure, neovascular glaucoma, buphthalmos
d. Hyphaema, vitreous haemorrhage
e. Aseptic orbital cellulitis
Pathology pT3 a. Choroid invasion massive >3mm / full width
b. Postlaminar nerve invasion not margin
c. Inner 2/3 scleral invasion
d. Full thickness sclera
Stage 3 Macroscopic regional extension
Clinical cT4 Ultrasonic invasion of orbit or optic nerve, moderate proptosis / orbital mass or recurrence
cN1 Regional lymph node involvement
Pathology pT4 Limited transcleral invasion of orbit, fat, muscle, conjunctiva, nerve margin free or minimal
pN1 Lymph node involvement, pre-auricular or cervical
Stage 4 Metastasis
Clinical cT4 Haemotogenous: skull tumour, paraplegia;
cM1 CNS: visible nerve resection margin involvement, massive orbital or adnexal tumour
Distant metastasis without microscopic confirmation
Pathology pT4 Major optic nerve involvement at resection margin indicating CNS involvement
pM1a Distant metastasis at any site with microscipic confirmation
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Fig. 1. Children with RB seen at Ruharo Eye Centre and enrolled into this study between Nov 2009 and Nov 2019 by year (A), home district or country (B) and by
approximate distance travelled to Ruharo (C). 2009 represents 1.5 months of enrolment and 2019 represents 11 months of enrolment. For a colour version of the
map, the reader is referred to the web version of this article.
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but in the interim, this is valuable for compassionate reasons and will
hopefully be temporary.
There is an unresolved question as to which is better, initial che-
moreduction for all, or immediate enucleation followed by selective
chemotherapy. Most eyes, even if the tumour is still intraocular, are at
enrolment already Group E in the International Classification of RB
(ICRB), as shown by the small number of conserved first eyes. This is
the most advanced group with no prospect of saveable sight and with a
tumour too large for likely cure by chemotherapy alone. Enucleation
therefore is vital and avoiding refusal is life-saving [16]. This study
confirms our previous experience that refusal is markedly reduced (but
not totally eliminated) by starting with chemoreduction. This allows
peer support by parents of children already satisfactorily treated. When
the parents are initially in a state of emotional shock on being told the
diagnosis, our counseling focusses on the response to chemotherapy,
delaying discussion of surgery until it becomes indicated. The excep-
tions are when pain and distress necessitate immediate surgery (which
in this situation is readily accepted), or if the issue is raised by the
parents. In the African cultural environment this benefit alone justifies
chemoreduction as the norm. It is also reasonable medically in the
setting of relatively advanced disease where minimal metastatic dis-
semination may be already occurring despite the tumour appearing still
intraocular, as shown by the reduced survival in Stage 2. A recent study
in Central America has reported favourably on chemoreduction [17].
The concern that it obscures need for further chemotherapy appears
unfounded as does the assertion that initial chemotherapy increases
mortality [18]. However, chemoreduction for all children does have
major drawbacks; it is labour-intensive and expensive and it carries a
risk of serious sepsis from leucopaenia although the frequency in this
study is very low. It also does not permit hindsight; an unknown pro-
portion of children might have been cured with surgery alone. There
are also cases where no tumour is subsequently found on histology
however, this does not rule out the diagnosis, notably in advanced
phthisis following sterile panophthalmitis or when the tissue on the
slides is fragmented. Initial chemotherapy also relies on accurate dif-
ferential diagnosis which can be equivocal even in experienced hands,
notably with atypical exudative retinopathy, so some without cancer
may be treated. Against these drawbacks has to be set the reduction of
the high mortality from refusal of enucleation and abandonment of
treatment by giving parents time to understand the condition. There are
no comparable published studies in this setting where immediate en-
ucleation with selective chemotherapy is standard so the question
which is better remains unresolved for lack of evidence.
The correct technique of enucleation is important, because if the
Table 1
Children with RB enrolled at Ruharo Eye Centre 15 Nov 2009 – 30 Nov 2019 showing number by laterality, sex, nationality and completeness of follow-up and the
median age at enrolment. The number of children receiving interrupted or delayed treatment is also shown.
Laterality N Males (%) Females (%) % aged 0−5 yr Ugandans (%) Complete follow-up (%) Non-compliant or >6 month delay (%)
Total 665 355 (53.4) 310 (46.6) 89.5 599 (90.1) 94.4 41 (6.2)
Unilateral 481 260 (54.1) 221 (45.9) 86.5 435 (90.4) 93.6 17 (3.5)
Bilateral 184 95 (51.6) 89 (48.4) 97.3 164 (89.1) 96.7 24 (13)
Follow-up is as defined in the text.
Fig. 2. Age at diagnosis (months) for children admitted to Ruharo Eye Centre between Nov 2009 and Nov 2019 with unilateral or bilateral disease. The x denotes
mean age.
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tumour has extended into the optic nerve, it is life-saving to section the
nerve at the orbital apex beyond the extension and so training is im-
portant. Facial appearance must also be considered because fear of fa-
cial disfigurement is a disincentive to accepting enucleation. Children
with an empty socket have a hard time at school and may refuse to
attend, so myoconjunctival attachment of the muscles to give mobility
of the prosthesis and an orbital implant are essential (details are in the
Supplement). We are currently gaining experience with dermofat grafts
from the buttock used secondarily for contracted sunken sockets. They
could also be beneficial as primary implants especially among those
under 4 years of age when the socket is still growing, but they add to
surgical and healing time. Stock prostheses obtained from India look
acceptable for most African children, and we are now setting up to
make custom-designed ones.
With massive orbital extension or visible optic nerve involvement to
the resection margin, metastasis has already occurred and only pallia-
tion is possible. Debulking by chemotherapy without surgery is possible
but this may consume the child’s last months of life. Formal exentera-
tion of the orbit is not life-saving at this point. Therefore, our program
uses immediate extended enucleation giving rapid relief and a return to
normal life. The terminal event is usually a rapid deterioration over
minutes or hours with features of raised intracranial pressure or hae-
morrhage. Infrequently there is slow decline over several weeks and
only rarely skull metastases or paraplegia, but offensive orbital recur-
rence has nearly disappeared. Good palliation for the final months is
usually achieved and is appreciated by the parents.
The curves of Fig. 4, as expected, show decreasing survival with
more advanced disease, and the precipitous fall in survival when the
tumour becomes extraocular at Stage 3. It also shows the risk of de-
clining treatment - some survive but with uncertain future. It is dis-
appointing that there is still not total survival in Stage 1 when the tu-
mour is fully intraocular and chemotherapy has been given, though the
great majority do survive. In Stage 2 better survival might also be ex-
pected, because even though there may be minimal metastatic spread
this should be eradicated by chemotherapy. A few deaths may be from
chemotherapy toxicity. Three bilateral children in remission have died
from osteogenic sarcoma, illustrating the on-going cancer risk that
children with a germline mutation face. Some unexpected deaths may
be from incorrect staging since information for criteria may be in-
complete. The criteria chosen for staging are provisional and still to be
validated. Validation will be complicated because the various systems
of classification do not harmonise closely [9–12]. Information from the
families suggests deaths in children with good prognosis and in re-
mission is usually from intercurrent infections or malaria, with social
dysfunction added. Uganda still has a substantial under-5 mortality; the
most recent estimate being 64 deaths per 1000 live births (6.4 %) [19].
When the tumour becomes extraocular (Stage 3) as yet few survive but
this could be changed when modern radiotherapy becomes more widely
available. Stage 4 as judged from massive orbital tumour or visible
nerve resection margin involvement signaling metastasis is incurable in
this setting. This has been shown also in India even when advanced
imaging and radiotherapy are available and justifies the decision for
palliation alone in Stage 4 disease [20]. Second line chemotherapeutic
protocols are available if the standard agents fail but as yet are of un-
certain efficacy. In contrast, the extended action of intravitreal therapy
for subretinal as well as vitreal seeding and even retinal tumours holds
promise of improving both survival and conservation of vision [21]. For
this we have changed from using melphalan because of toxicity and
now use topotecan with apparent equal success [22].
Children with bilateral disease face blindness if bilateral enucleation
is necessary to save life. This is a common situation, as they may have
advanced bilateral disease at enrolment even if young infants and they
may continue to produce new tumours since they have a germline
mutation. Parents understandably find it very difficult to accept second
enucleation when there is still a glimmer of sight and so may delay until
too late. Testing acuity in young children is difficult, so many are es-
timated from fundal appearance. The four broad grades we have used
broadly predict educational requirements: Grade 1 children with full
Fig. 3. Distribution of children with RB by number of eyes
affected and stage of disease in the most severely affected eye.
Bars are labelled with the proportion of children in each stage
by laterality. ICRB groups AeD are represented among
Intraocular children (although most were groups C and D)
whereas all other children were ICRB group E.
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central vision but variable peripheral impairment can access normal
education, grade 2 (moderate impairment) children can use print
education with low vision devices if necessary, grade 3 (major im-
pairment) children can mostly use non-visual media (computer or
Braille), and grade 4 (blind) children will require entirely non-visual
media. Table 2 shows that vision can improve between enrolment and
end of primary treatment with chemotherapy, and that those with
normal vision usually retain it. Fig. 5 traces the period of retention of
Fig. 4. Survival of children with RB. Kaplan-Meier estimates grouped by modified IRSS stage and stratified by number of eyes affected. Staging based on most
severely affected eye in children with bilateral disease. Children whose start of treatment was delayed or later interrupted by at least six months are presented
separately. P-values indicate result of a log-rank test comparing the survival of children with unilateral and bilateral disease within each stage. Shaded areas indicate
95 % point-wise confidence limits. For a colour version of this figure, the reader is referred to the web version of this article.
Table 2
Vision assessments for bilateral children at time of enrolment and at the end of primary treatment†.
Vision at enrolment Vision after primary treatment
n Full Vision Moderate Impairment Severe Impairment Blind
Full Vision 71 71 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Moderate Impairment 19 5 (26.3) 13 (68.4) 1 (5.3) 0 (0.0)
Severe Impairment 46 7 (15.2) 10 (21.7) 22 (47.8) 7 (15.2)
Blind 48 0 (0.0) 0 (0.0) 1 (2.1) 47 (97.9)
Total 184 83 (45.1) 23 (12.5) 24 (13.0) 54 (29.3)
† Primary treatment ending defined as the end of the initial chemotherapy courses (ranged from 1 to 6 courses) with one calendar month for each course.
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vision after primary treatment stratified by grade at that point. Even if
sight is ultimately lost, conservation for a period may be beneficial for
the child’s development. Most surviving bilateral children have either
normal vision (49.5 % of survivors) or are blind (39.5 %), with only few
in intermediate grades. Amongst these survivors, just over half retained
full central vision, but over a third were blind and will need special
education, which must be considered by financial sponsors.
Previously, complete histology was available only intermittently
affecting the accuracy of staging however improved histology is now
available. Overcoming the technical difficulty of sectioning eyes with
their tough sclera but soft contents remains a challenge although im-
provements are being made. Accurate histology to identify high risk
features is especially important if treating RB with initial enucleation
alongside chemotherapy selecting children according to risk. The ab-
sence of accurate histology is another indication for routine chemor-
eduction. It is instructive for surgeons themselves to examine and
measure specimens carefully at time of surgery, and to make the pre-
liminary grossing cut after fixation and inking the optic nerve resection
margin to assess the tumour. Categorising histopathological findings in
a TNM format is essential [9,12]. Further understanding is gained if the
pathologist and the clinician review the pathological and clinical
findings together to decide on a therapeutic approach.
The workload for such a program is ever increasing. Expertise can
be gained by staff spending time with an already established program.
There should ideally be a dedicated ward and an uninterrupted supply
of medicines. Surgery with good anaesthesia must be available
(ketamine is safe and convenient), as must cryotherapy and a diode
laser with head-mounted delivery. Children with bilateral tumours,
although a minority, make a heavy contribution to workload because
interventions to conserve the second eye to avoid blindness may take
years of multiple admissions and may even then fail. Another heavy
contribution to workload is the need to repeatedly examine children
whose primary treatment is completed successfully so as to identify
recurrent or new tumours which could be ablated whilst still small. This
applies especially to bilateral (heritable) children where new tumours
can develop over several years, usually up to about 7 years of age but as
late as 17 years old as seen in this study. Siblings should also be ex-
amined especially if there is a family history or bilaterality. The follow-
up schedules recommended in high income countries are unrealistic
and have to be modified for programs with many children [21]. This
workload could be reduced if genetic information was obtained, to
concentrate follow up on those with a germline mutation. Currently this
is not easy to access and in the African cultural environment great care
must be taken not to increase blame which may already exist within the
family.
The overall conclusion is that at the present time it is possible to
establish more treatment centres in under-served parts of sub-Saharan
Africa; we have assisted this in Rwanda and Burundi. In Uganda, the
Eye Department of Mulago Hospital along with the Uganda Cancer
Institute in the capital city, Kampala, are developing their program.
Further dispersed centres using non-specialists are needed but the ob-
stacles are getting sufficient staff to undertake the heavy workload and
Fig. 5. Time vision was retained post-primary-treatment for
children with bilateral disease stratified by visual assessment
at end of primary treatment and stage of disease. Stage of
disease based on most-severely affected eye; children blind
after primary treatment have been excluded. Blue bars in-
dicate time with at least some vision retained; red bars denote
time when child was blind. Gray bars indicate children who
retained some vision after primary treatment and were blind
at last contact but the time when the child transitioned from
having some sight to having no sight could not be determined.
(For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this ar-
ticle).
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securing adequate funding which must include social costs like food
and transport, not just treatment. Our program had been budgeted since
the start at €1000 per newly diagnosed child, but with rising costs
€1400 is now necessary. This sounds too costly in Africa but our pre-
vious cost/benefit analysis was favourable and we are now planning a
larger in-depth analysis [7]. It must be emphasised that success depends
on adopting strategies adapted to resource limited regions. These in-
clude using trained, but non-specialist, nursing staff supervised by se-
nior, but generalist, clinicians, and affordable off-patent drugs. It en-
compasses a holistic approach with sensitive counselling, treatment in
groups allowing peer support from other families, adequate financial
support and children returning home between treatments so parents
can care for the whole family. With the current global emphasis on
addressing non-communicable disease, the time is ripe for these de-
velopments.
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Technology. The program has since used the orginal protocols for
clinical management and data collection.
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